Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Post by Indomitableon Aug 11, 2016 12:44am
100 Views
Post# 25129434

One last thing...

One last thing...Lee said in his last video interview which wasn't so long ago that they had enough money to keep em going for at least a year no problem.

You all do realise that they are a R&D compnany and that most R&D companies can take copious years leading possibly well over a decade doing phase 1,2,3 studies before they even have a licenced product out their they are seilling and that during this time their company still magically can be worth 100's of millions of dollars or more based on nothing but future potential. 

One great thing about Replicel is in their  approach as an R&D company in how they finance themselves by collaborating with other companies and having those companies pay Replicel's way instead. By Replicel doing what they are doing, they actually see actual real money given to them from other collaborating companies before they even have a product out on the shelf unlike the majority of other 1000's of R&D companies. 
Indomitable Cool

Bullboard Posts